JAK2 (Janus Kinase 2) belongs to the emerging family of non-receptor Janus tyrosine kinases, which regulate a spectrum of cellular functions downstream of activated cytokine receptors in the lympho-hematopoietic system. Immunological stimuli, such as interferons and cytokines, induce recruitment of Stat transcription factors to cytokine receptor-associated JAK2. JAK2 then phosphorylates proximal Stat factors, which subsequently dimerize, translocate to the nucleus and bind to CIS elements upstream of target gene promoters to regulate transcription. The canonical JAK/Stat pathway is integral to maintaining a normal immune system by stimulating proliferation, differentiation, survival and host resistance to pathogens. Altering JAK/Stat signaling to reduce cytokine induced pro-inflammatory responses represents an attractive target for anti-inflammatory therapies. Within the JAK2 kinase domain, there is a region that has considerable sequence homology to the regulatory region of the insulin receptor.
Product Information
Format
Unpurified
Control
Immunoprecipitation pellets from Jurkat cell lysate +GM-CSF
Presentation
Rabbit Monoclonal in buffer containing 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl containing 40% Glycerol, 0.01% sodium azide and 0.05% BSA.
Applications
Application
Please note that this product will not be available for sale after March 15, 2015. Please select one of the other antibodies against this target.
Key Applications
Immunoprecipitation
Western Blotting
Immunohistochemistry (Paraffin)
Immunocytochemistry
Application Notes
Immunohistochemistry Analysis: A 1:50-100 dilution from a previous lot detected Jak2 in human lung adenocarcinoma tissue.
Dot Blot Analysis: Dot Blot analysis from a previous lot detected Jak2 on immunogen phospho-peptide and non-phospho peptide.
Immunocytochemistry Analysis: A 1:50-100 dilution from a previous lot was used in IC.
Immunoprecipitation Analysis: A 1:50 dilution from a previous lot was used in IP.
Biological Information
Immunogen
Phospho-synthetic peptide corresponding to residues surrounding Tyr1007 and Tyr1008 of human Jak2.
Epitope
Phosphorylated Tyr1007/Tyr1008
Clone
E132
Host
Rabbit
Specificity
The antibody only detects Jak2 phosphorylated on Tyr1007 and Tyr1008.
FUNCTION:Plays a role in leptin signaling and control of body weight By similarity. Tyrosine kinase of the non-receptor type, involved in interleukin-3 and probably interleukin-23 signal transduction. CATALYTIC ACTIVITY:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate. SUBUNIT STRUCTURE:Interacts with SIRPA and SH2B1 By similarity. Interacts with IL23R, SKB1 and STAM2. SUBCELLULAR LOCATION:Endomembrane system; Peripheral membrane protein By similarity. Note: Wholly intracellular, possibly membrane associated By similarity. TISSUE SPECIFICITY:Expressed in blood, bone marrow and lymph node. DOMAIN:Possesses two phosphotransferase domains. The second one probably contains the catalytic domain By similarity, while the presence of slight differences suggest a different role for domain 1. PTM:Leptin promotes phosphorylation on tyrosine residues, including phosphorylation on Tyr-813 By similarity. INVOLVEMENT IN DISEASE:Chromosomal aberrations involving JAK2 are found in both chronic and acute forms of eosinophilic, lymphoblastic and myeloid leukemia. Translocation t(8;9)(p22;p24) with PCM1 links the protein kinase domain of JAK2 to the major portion of PCM1. Translocation t(9;12)(p24;p13) with ETV6.Defects in JAK2 are a cause of susceptibility to Budd-Chiari syndrome [MIM:600880]. Budd-Chiari syndrome is a spectrum of disease states, including anatomic abnormalities and hypercoagulable disorders, resulting in hepatic venous outflow occlusion. Clinical manifestations observed in the majority of patients include hepatomegaly, right upper quadrant pain, and abdominal ascites.
Defects in JAK2 are associated with polycythemia vera (PV) [MIM:263300]. PV, the most common form of primary polycythemia, is caused by somatic mutation in a single hematopoietic stem cell leading to clonal hematopoiesis. PV is a myeloproliferative disorder characterized predominantly by erythroid hyperplasia, but also by myeloid leukocytosis, thrombocytosis, and splenomegaly. Familial cases of PV are very rare and usually manifest in elderly patients.
Defects in JAK2 gene may be a cause of essential thrombocythemia (ET) [MIM:187950]. ET is characterized by elevated platelet levels due to sustained proliferation of megakaryocytes, and frequently lead to thrombotic and haemorrhagic complications.
Defects in JAK2 are associated with familial myelofibrosis [MIM:254450]. Myelofibrosis with myeloid metaplasia is a myeloproliferative disease with annual incidence of 0.5-1.5 cases per 100,000 individuals and age at diagnosis around 60 (an increased prevalence is noted in Ashkenazi Jews). Clinical manifestations depend on the type of blood cell affected and may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension.
Defects in JAK2 are a cause of acute myelogenous leukemia (AML) [MIM:601626]. AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development. SEQUENCE SIMILARITIES:Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily.
Contains 1 FERM domain.
Contains 1 protein kinase domain.
Contains 1 SH2 domain.
Product Usage Statements
Quality Assurance
Evaluated by Western Blot on immunoprecipitation pellets from Jurkat cell lysate +GM-CSF.
Western Blot Analysis: A 1:5,000-10,000 dilution of this antibody was used to detect Jak2 in immunoprecipitation pellets from Jurkat cell lysate +GM-CSF.
Usage Statement
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage Conditions
Stable for 1 year at -20ºC from date of receipt.
Handling Recommendations: Upon first thaw, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance. Note: Variability in freezer temperatures below -20°C may cause glycerol containing solutions to become frozen during storage.
JAK2 (Janus Kinase 2) belongs to the emerging family of non-receptor Janus tyrosine kinases, which regulate a spectrum of cellular functions downstream of activated cytokine receptors in the lympho-hematopoietic system. Immunological stimuli, such as interferons and cytokines, induce recruitment of Stat transcription factors to cytokine receptor-associated JAK2. JAK2 then phosphorylates proximal Stat factors, which subsequently dimerize, translocate to the nucleus and bind to CIS elements upstream of target gene promoters to regulate transcription. The canonical JAK/Stat pathway is integral to maintaining a normal immune system by stimulating proliferation, differentiation, survival and host resistance to pathogens. Altering JAK/Stat signaling to reduce cytokine induced pro-inflammatory responses represents an attractive target for anti-inflammatory therapies. Within the JAK2 kinase domain, there is a region that has considerable sequence homology to the regulatory region of the insulin receptor.
Product Information
Format
Unpurified
Control
Immunoprecipitation pellets from Jurkat cell lysate +GM-CSF
Presentation
Rabbit Monoclonal in buffer containing 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl containing 40% Glycerol, 0.01% sodium azide and 0.05% BSA.
Applications
Application
Please note that this product will not be available for sale after March 15, 2015. Please select one of the other antibodies against this target.
Key Applications
Immunoprecipitation
Western Blotting
Immunohistochemistry (Paraffin)
Immunocytochemistry
Application Notes
Immunohistochemistry Analysis: A 1:50-100 dilution from a previous lot detected Jak2 in human lung adenocarcinoma tissue.
Dot Blot Analysis: Dot Blot analysis from a previous lot detected Jak2 on immunogen phospho-peptide and non-phospho peptide.
Immunocytochemistry Analysis: A 1:50-100 dilution from a previous lot was used in IC.
Immunoprecipitation Analysis: A 1:50 dilution from a previous lot was used in IP.
Biological Information
Immunogen
Phospho-synthetic peptide corresponding to residues surrounding Tyr1007 and Tyr1008 of human Jak2.
Epitope
Phosphorylated Tyr1007/Tyr1008
Clone
E132
Host
Rabbit
Specificity
The antibody only detects Jak2 phosphorylated on Tyr1007 and Tyr1008.
FUNCTION:Plays a role in leptin signaling and control of body weight By similarity. Tyrosine kinase of the non-receptor type, involved in interleukin-3 and probably interleukin-23 signal transduction. CATALYTIC ACTIVITY:ATP + a [protein]-L-tyrosine = ADP + a [protein]-L-tyrosine phosphate. SUBUNIT STRUCTURE:Interacts with SIRPA and SH2B1 By similarity. Interacts with IL23R, SKB1 and STAM2. SUBCELLULAR LOCATION:Endomembrane system; Peripheral membrane protein By similarity. Note: Wholly intracellular, possibly membrane associated By similarity. TISSUE SPECIFICITY:Expressed in blood, bone marrow and lymph node. DOMAIN:Possesses two phosphotransferase domains. The second one probably contains the catalytic domain By similarity, while the presence of slight differences suggest a different role for domain 1. PTM:Leptin promotes phosphorylation on tyrosine residues, including phosphorylation on Tyr-813 By similarity. INVOLVEMENT IN DISEASE:Chromosomal aberrations involving JAK2 are found in both chronic and acute forms of eosinophilic, lymphoblastic and myeloid leukemia. Translocation t(8;9)(p22;p24) with PCM1 links the protein kinase domain of JAK2 to the major portion of PCM1. Translocation t(9;12)(p24;p13) with ETV6.Defects in JAK2 are a cause of susceptibility to Budd-Chiari syndrome [MIM:600880]. Budd-Chiari syndrome is a spectrum of disease states, including anatomic abnormalities and hypercoagulable disorders, resulting in hepatic venous outflow occlusion. Clinical manifestations observed in the majority of patients include hepatomegaly, right upper quadrant pain, and abdominal ascites.
Defects in JAK2 are associated with polycythemia vera (PV) [MIM:263300]. PV, the most common form of primary polycythemia, is caused by somatic mutation in a single hematopoietic stem cell leading to clonal hematopoiesis. PV is a myeloproliferative disorder characterized predominantly by erythroid hyperplasia, but also by myeloid leukocytosis, thrombocytosis, and splenomegaly. Familial cases of PV are very rare and usually manifest in elderly patients.
Defects in JAK2 gene may be a cause of essential thrombocythemia (ET) [MIM:187950]. ET is characterized by elevated platelet levels due to sustained proliferation of megakaryocytes, and frequently lead to thrombotic and haemorrhagic complications.
Defects in JAK2 are associated with familial myelofibrosis [MIM:254450]. Myelofibrosis with myeloid metaplasia is a myeloproliferative disease with annual incidence of 0.5-1.5 cases per 100,000 individuals and age at diagnosis around 60 (an increased prevalence is noted in Ashkenazi Jews). Clinical manifestations depend on the type of blood cell affected and may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension.
Defects in JAK2 are a cause of acute myelogenous leukemia (AML) [MIM:601626]. AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development. SEQUENCE SIMILARITIES:Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily.
Contains 1 FERM domain.
Contains 1 protein kinase domain.
Contains 1 SH2 domain.
Product Usage Statements
Quality Assurance
Evaluated by Western Blot on immunoprecipitation pellets from Jurkat cell lysate +GM-CSF.
Western Blot Analysis: A 1:5,000-10,000 dilution of this antibody was used to detect Jak2 in immunoprecipitation pellets from Jurkat cell lysate +GM-CSF.
Usage Statement
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage Conditions
Stable for 1 year at -20ºC from date of receipt.
Handling Recommendations: Upon first thaw, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance. Note: Variability in freezer temperatures below -20°C may cause glycerol containing solutions to become frozen during storage.
京公网安备11010802025653 版权所有：北京逸优科技有限公司
